Halozyme names James M. Daly as director

HALO•2026-10-02

Halozyme Therapeutics named James M. Daly to its board. An initial insider ownership filing dated Sept. 28, 2026, lists no securities beneficially owned by Daly.

1. Board appointment

Halozyme Therapeutics named James M. Daly as a director. An initial insider ownership filing dated Sept. 28, 2026, lists Daly as a director and reports no securities beneficially owned as of that date.

Sources

Halozyme names James M. Daly as director

Sec

Halozyme names James M. Daly as director

1. Board appointment

Related News

US FAA says Boeing 737 MAX software glitch poses no safety issue

Nocera publishes restated quarterly report amendment (Form 10-Q/A)

Silo Pharma issues warrant for up to 300,000 shares in unregistered sale under asset purchase deal

Sources

Halozyme names James M. Daly as director

Tantech says Yefang Zhang resigns as director and chairman effective Oct. 1

SOBRsafe postpones annual general meeting until further notice